Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
12 pending office actions • 3 clients • 12 examiners • 9 art units • 0 of 12 (0%) have an AI response strategy ready • 9 patents granted in the last 365 days
CANTOR COLBURN LLP - UCONN operates in the Biotechnology & Pharmaceuticals technology area, utilizing the firm's broad experience of 74190 career applications. This specific designation currently manages 13 pending office actions, representing a focused set of active matters. The firm's history across a wide range of technical fields provides a context for its work in biotechnology and pharmaceutical patents.
The firm reports a resolved allowance rate pct of 88.07, indicating success in securing patent rights. This success is achieved with an avg_office_actions_per_allowance of 3.16, suggesting that the firm typically navigates the examination process in a specific number of office actions. The 88.07 resolved allowance rate pct is a key indicator of the firm's effectiveness in the Biotechnology & Pharmaceuticals sector. With 74190 career applications, the 3.16 avg_office_actions_per_allowance provides a reliable benchmark for the expected duration of the prosecution cycle. These data points offer a view of the firm's performance and capacity.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 3 (25%) |
| §103 only | 1 (8%) |
| §112 only | 2 (17%) |
| Double-patenting + other | 1 (8%) |
| Multi-statute (no §101) | 5 (42%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SIRCAR, ALISHA JITENDRA | 1 | 58.1% | +58.1% |
| STEPHENS, JACQUELINE F | 1 | 75.6% | +14.8% |
| ALLEN, SARAH ELIZABETH | 1 | 57.1% | +50.0% |
| CRAIGO, WILLIAM A | 1 | 49.2% | +38.2% |
| ROGERS, JAMES WILLIAM | 1 | 46.2% | +22.3% |
| BRANDT, DAVID NELSON | 1 | 70.1% | +49.0% |
| IQBAL, SYED TAHA | 1 | 79.9% | +21.3% |
| EVANS, CHRISTOPHER RYAN | 1 | 60.9% | +64.3% |
| PRICE, NATHAN R | 1 | 53.4% | +38.9% |
| MCCORMICK, CATHERINE LYNN | 1 | 50.0% | +42.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18658442 | DERIVATION OF ELECTRODERMAL ACTIVITY RESPONSE FROM AN ELECTROCARDIOGRAM SIGNAL | SIRCAR, ALISHA JITENDRA | 23d overdue |
| 18658102 | DISSOLUTION ADAPTER, METHOD OF MANUFACTURE THEREOF AND METHOD OF USE THEREOF | STEPHENS, JACQUELINE F | — |
| 18491536 | INHIBITORS OF CYTOCHROME P450 FAMILY 7 SUBFAMILY B MEMBER 1 (CYP7B1) FOR USE IN MOBILIZATION OF HEMATOPOIETIC STEM AND PROGENITOR CELLS | ROGERS, JAMES WILLIAM | — |
| 18474544 | NASOGASTRIC DEVICE AND METHOD | BRANDT, DAVID NELSON | — |
| 18234099 | SOLID POROUS PENTACIL-ZEOLITE COMPOSITE MATERIALS | IQBAL, SYED TAHA | — |
| 18351317 | ULTRASENSITIVE SENSING METHOD FOR DETECTION OF BIOMOLECULES | EVANS, CHRISTOPHER RYAN | — |
| 18027384 | IMPLANTABLE MEDICAL DEVICES WITH ENHANCED BIOCOMPATIBILITY | PRICE, NATHAN R | — |
| 18017551 | BIOMEDICAL BIG DATA ANALYSIS PROGRAM | PLAYER, ROBERT AUSTIN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18658442 | DERIVATION OF ELECTRODERMAL ACTIVITY RESPONSE FROM AN ELECTROCARDIOGRAM SIGNAL | SIRCAR, ALISHA JITENDRA | 23d overdue |
| 18658102 | DISSOLUTION ADAPTER, METHOD OF MANUFACTURE THEREOF AND METHOD OF USE THEREOF | STEPHENS, JACQUELINE F | — |
| 18630651 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF GLYCOGEN STORAGE DISORDERS | ALLEN, SARAH ELIZABETH | — |
| 18535288 | PHOTO-CROSSLINKABLE PLANT-BASED MATERIALS, METHODS OF MANUFACTURE THEREOF AND ARTICLES COMPRISING THE SAME | CRAIGO, WILLIAM A | — |
| 18491536 | INHIBITORS OF CYTOCHROME P450 FAMILY 7 SUBFAMILY B MEMBER 1 (CYP7B1) FOR USE IN MOBILIZATION OF HEMATOPOIETIC STEM AND PROGENITOR CELLS | ROGERS, JAMES WILLIAM | — |
| 18474544 | NASOGASTRIC DEVICE AND METHOD | BRANDT, DAVID NELSON | — |
| 18234099 | SOLID POROUS PENTACIL-ZEOLITE COMPOSITE MATERIALS | IQBAL, SYED TAHA | — |
| 18351317 | ULTRASENSITIVE SENSING METHOD FOR DETECTION OF BIOMOLECULES | EVANS, CHRISTOPHER RYAN | — |
| Client (Assignee) | Pending OAs |
|---|---|
| University of Connecticut | 10 |
| CONNECTICUT CHILDREN'S MEDICAL CENTER | 1 |
| BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 1 |
| Art Unit | Apps |
|---|---|
| 3783 | 2 |
| 3792 | 1 |
| 3781 | 1 |
| 1615 | 1 |
| 1618 | 1 |
| 1736 | 1 |
| 1677 | 1 |
| 1638 | 1 |
| 1637 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18658442 | DERIVATION OF ELECTRODERMAL ACTIVITY RESPONSE FROM AN ELECTROCARDIOGRAM SIGNAL | UNIVERSITY OF CONNECTICUT | SIRCAR, ALISHA JITENDRA | 3792 | §101§103 | Final Rejection | 23d overdue | Pending | May 08, 2024 |
| 18658102 | DISSOLUTION ADAPTER, METHOD OF MANUFACTURE THEREOF AND METHOD OF USE THEREOF | UNIVERSITY OF CONNECTICUT | STEPHENS, JACQUELINE F | 3781 | §102§103§112 | Non-Final OA | — | Pending | May 08, 2024 |
| 18630651 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF GLYCOGEN STORAGE DISORDERS | UNIVERSITY OF CONNECTICUT | ALLEN, SARAH ELIZABETH | §112 | Non-Final OA | — | Pending | Apr 09, 2024 | |
| 18535288 | PHOTO-CROSSLINKABLE PLANT-BASED MATERIALS, METHODS OF MANUFACTURE THEREOF AND ARTICLES COMPRISING THE SAME | UNIVERSITY OF CONNECTICUT | CRAIGO, WILLIAM A | 1615 | §102§103§112DP | Final Rejection | — | Pending | Dec 11, 2023 |
| 18491536 | INHIBITORS OF CYTOCHROME P450 FAMILY 7 SUBFAMILY B MEMBER 1 (CYP7B1) FOR USE IN MOBILIZATION OF HEMATOPOIETIC STEM AND PROGENITOR CELLS | UNIVERSITY OF CONNECTICUT | ROGERS, JAMES WILLIAM | 1618 | §102§103 | Non-Final OA | — | Pending | Oct 20, 2023 |
| 18474544 | NASOGASTRIC DEVICE AND METHOD | Connecticut Children'S Medical Center | BRANDT, DAVID NELSON | 3783 | §101§103§112 | Non-Final OA | — | Pending | Sep 26, 2023 |
| 18234099 | SOLID POROUS PENTACIL-ZEOLITE COMPOSITE MATERIALS | The University of Connecticut | IQBAL, SYED TAHA | 1736 | §102§103 | Non-Final OA | — | Pending | Aug 15, 2023 |
| 18351317 | ULTRASENSITIVE SENSING METHOD FOR DETECTION OF BIOMOLECULES | UNIVERSITY OF CONNECTICUT | EVANS, CHRISTOPHER RYAN | 1677 | §102§103§112 | Non-Final OA | — | Pending | Jul 12, 2023 |
| 18027384 | IMPLANTABLE MEDICAL DEVICES WITH ENHANCED BIOCOMPATIBILITY | UNIVERSITY OF CONNECTICUT | PRICE, NATHAN R | 3783 | §103§112 | Non-Final OA | — | Pending | Mar 21, 2023 |
| 18041271 | ANTI-SEED PNAS AND MICRORNA INHIBITION | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | MCCORMICK, CATHERINE LYNN | 1638 | §103 | Final Rejection | — | Pending | Feb 10, 2023 |
| 18017551 | BIOMEDICAL BIG DATA ANALYSIS PROGRAM | UNIVERSITY OF CONNECTICUT | PLAYER, ROBERT AUSTIN | §101§103§112 | Non-Final OA | — | Pending | Jan 23, 2023 | |
| 18006235 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | UNIVERSITY OF CONNECTICUT | ANGELL, JON E | 1637 | §112 | Non-Final OA | — | Pending | Jan 20, 2023 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial